Zunsemetinib is under clinical development by Aclaris Therapeutics and currently in Phase II for Psoriatic Arthritis. According to GlobalData, Phase II drugs for Psoriatic Arthritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zunsemetinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zunsemetinib overview

Zunsemetinib (ATI-450, CDD-450) is under development for the treatment of pyoderma gangrenosum, chronic inflammation, psoriasis, psoriatic arthritis, inflammatory bowel disease, crohn's colitis, rheumatoid arthritis, and hidradenitis suppurativa and, metastatic breast cancer and chemotherapy-induced bone loss, pancreatic cancer and gout. It is administered through oral route. The drug candidate targets MAP2K2 which regulates MK2-PI pathway. The drug candidate is developed based on KINect platform technology which works by identifying protein kinase inhibiting drugs using structure based drug design.

The drug candidate was also under development for the treatment of neutrophilic dermatosis, Cryopyrin-associated periodic syndromes like familial cold autoinflammatory syndrome, muckle-wells syndrome, or neonatal onset multisystem inflammatory disease.

Aclaris Therapeutics overview

Aclaris Therapeutics is bio-pharmaceutical company focused on identifying, developing and commercializing small molecule therapies for immuno-inflammatory conditions. Its lead product, ESKATA is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company’s pipeline products include A-101, ATI-1777-oral JAK 1/3 inhibitor, ATI-501, ATI-450-oral MK2 pathway inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17.Aclaris Therapeutics’ pipeline products are used for the treatment of common warts, alopecia areata, androgenetic alopecia, psoriasis, arthritis, gangrenosum, inflammatory bowel disease and atopic dermatitis. The company also develops investigational drugs to treat skin and hair conditions. Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, the US.

For a complete picture of Zunsemetinib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.